Acute myeloid leukaemia: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• FLT3 36
• TP53 9
• NPM1 27
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• NRF2 0
• PD-1 4
• PPAR 0
• CXCR4 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Sweden· EU contribution €2,000,000· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting bioactive lipids to overcome leukemia immune evasion and improve allogeneic hematopoietic stem cell transplantation outcomes (LIFE)

  Universitat Basel· Basel, Switzerland· EU contribution €1,499,511· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Integrating DNA Methylation and Drug Abundance at Single-Cell Resolution to Predict Cancer Drug Sensitivity (EPI-SENSOR)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €1,499,423· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Perturbation-based Phosphoproteomics to Study Drug Response Heterogeneity (PerturbPhos)

  Universitatsklinikum Jena· Jena, Germany· EU contribution €1,491,735· until Sept 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  PERSONALISED NUTRITIONAL CARE FOR OLDER PATIENTS WITH LEUKAEMIA OR PANCREATIC CANCER – A PRAGMATIC IMPLEMENTATION TRIAL TO IMPROVE QUALITY OF LIFE (NutriCa65)

  Universitetet I Bergen· Bergen, Norway· EU contribution €5,296,543· until Aug 2030· 9 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Identification of novel genetic regulators governing leukaemic transformation from myeloid proliferative neoplasms (MPN2AML)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €313,395· until Aug 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias (LeukemiaBlock)

  Masarykova univerzita· Brno, Czechia· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Revolutionizing AML Therapy - A First-in-Class CK1 Inhibitor for Relapsed Refractory Patients (REACT-CK1)

  Casinvent Pharma A.s.· Brno, Czechia· EU contribution €485,034· until Jul 2028

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  A First-in-Class MCL-1 degrader to promote apoptosis in therapy-resistant liquid and solid tumours (CT-03)

  Captor Therapeutics Spolka Akcyjna· Wroclaw, Poland· EU contribution €2,499,875· until Dec 2027

10 of 26 running projects, newest first. Listed amounts together: €53.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

  NCT03576547· M.D. Anderson Cancer Center· Updated 8 May 2025

  “The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 17
• Gene Expression Profiling 85
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 88
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 160
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• Single-cell RNA sequencing reveals immunological heterogeneity of the tumor microenvironment in acute myeloid leukemia.

  Adv Clin Exp Med, Jul 2026

• Single-cell RNA sequencing reveals chemotherapy-induced apoptosis in acute myeloid leukemia via B cell depletion and M2 to M1 macrophage repolarization.

  Hum Genomics, Jun 2026

• Clinical Utility of Whole RNA Sequencing for Fusion Detection in Acute Leukemia.

  Cells, Jun 2026

• Single-nucleus RNA sequencing reveals the cellular composition and the mechanism underlying adrenal myelolipoma.

  Endocrine, May 2026

• Identification and validation of lymphangiogenesis-related genes for predicting acute myeloid leukemia prognosis: insights from bulk RNA sequencing and single-cell RNA sequencing analyses.

  Clin Exp Med, Mar 2026

• Identification and experimental validation of biomarkers for acute myeloid leukemia based on single-cell RNA sequencing data.

  Mol Cell Probes, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.